[ASSESSMENT OF INDICATORS FOR INTERFERON SYSTEM IN PATIENTS WITH COMMON FORMS OF PULMONARY TUBERCULOSIS RECEIVING COMPLEX THERAPY WITH CYCLOFERON].
We have evaluated the efficacy of cycloferon inclusion in the complex therapy of newly diagnosed patients with common forms of pulmonary tuberculosis, based on monitoring of the number of monocytes with receptors to interferon-gamma (flow cytometry) and the concentration of interferon-gamma in the serum (ELISA). For this purpose, a group of 36 patients (18 patients received standard chemotherapy, and 18 additionally received 600 mg cycloferon tablets 3 times per week) was examined for 3 months. Control group consisted of 18 apparently healthy patients. The study did not include patients with multiple or extensively drug-resistant M. tuberculosis strains. The analysis of results showed a statistically significant positive dynamics of the level of monocyte receptors to interferon-gamma in patients receiving cycloferon as manifested by an increase in their number in the first 2 months of therapy (period of clinical manifestations of the disease), followed by a decrease in the 3rd months of treatment, which corresponds to clinical improvement, in contrast to patients treated with standard chemotherapy alone.